It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific ... IgM antibody targeting CD38 and CD3 proteins for ...
It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific ... IgM antibody targeting CD38 and CD3 proteins for ...
This composite flow cytometric panel illustrates the bone marrow of a newly diagnosed primary plasma cell leukemia patient demonstrating CD38 +, λ-a-restricted, CD20-plasma cells.
Epstein-Barr virus (EBV)—the prototypical human tumor virus—is responsible for 1–2% of the global cancer burden, but divergent strains seem to exist in different geographical regions with distinct ...
Two populations of B cells (CD19+, CD20+) were identified: naïve (IgD+) and memory B cells (CD27+), as well as a small cluster of plasmablasts (CD27+, CD38+). Naïve B cells were consistently expanded ...
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter company to discontinue development of the program. Back in 2019 ...
While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...
Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...
Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback